The present invention relates to compounds with high chemical stability and methods for inhibiting the pathological activity of NETs in a subject. In particular, the invention relates to compounds with high chemical stability, uses thereof and methods for inhibiting or ameliorating NET mediated ailments (such as, for example, sepsis, systemic immune response syndrome (SIRS) and ischemia reperfusion injury (IRI)). More particularly, the invention relates to methods and uses of a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus, wherein the presence of the substituent results in a molecule with high chemical stability without affecting the ability of the molecule to be effective in the therapy of NET mediated ailments. For example, the present invention relates to methods and uses of β-O-methyl cellobioside sulfate (mCBS) or a pharmaceutically acceptable salt thereof (e.g., mCBS.Na), in the therapy of a range of NET mediated ailments in subjects.

The present invention provides apothecarial compositions and treatments for medical conditions and/or for cosmetic applications.

The present invention provides apothecarial compositions and treatments for medical conditions and/or for cosmetic applications.

The present invention related to a composition comprising an extract of alder tree or the isolated compounds therefrom for treating and preventing skeleton muscle disease and the use thereof. It has been confirmed that the inventive extract/compounds showed potent improving or treating effect on muscle loss through various in vitro test and animal model tests, for example, Stimulation effect of inventive extract/compounds on the initiation effect of myoblast differentiation (Experimental Example 1, 3 and 4), confirming that inventive extract/compounds increases the number of cylinder-shaped multinucleated myotubes, resulting in promoting muscle cell differentiation; Study on p38 MAPK signaling system mechanism of inventive extract/compounds for promoting myoblast differentiation (Experimental Example 2 and 5); Inhibitory effect of inventive extract/compounds on muscle loss (Experimental Example 6 and 7); improving effect on motility in animal model of muscle loss (In vivo) (Experimental Example 8) confirming that s that inventive extract/compounds promotes muscle cell differentiation as well as improves motor capacity decline and muscle loss. Therefore, the inventive extract/compounds of the present invention can be usefully used in a pharmaceutical composition, health functional food, and health supplement food for preventing or treating on skeleton muscle disease.

Disclosed are novel multi-substituent psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The compounds may be produced by reacting a reactant psilocybin derivative with a substituent containing compound.

An infant formula milk powder is rich in milk fat globule membrane protein, phospholipids, and oligosaccharides. A preparation method includes using raw cow milk as raw material, cleaning and pre-sterilizing raw cow milk, adding MFGM-rich whey protein powder, α-lactalbumin powder, galactooligosaccharides, polyfructoses and other ingredients into the pre-sterilized raw cow milk, and performing pre-sterilization, homogenization, sterilization, concentration, and spray drying. By means of formula adjustment, the contents of biologically active substances having special functional components such as MFGM-protein, lactoferrin, α-lactalbumin, total galactooligosaccharide, total polyfructose, sialic acid, total phospholipid, sphingomyelin, lecithin, phosphatidylserine, phosphatidylethanolamines, phosphatidylinositol, ganglioside, triglyceride and diglyceride in the infant formula milk powder are increased, thereby facilitating the colonization of probiotics in the intestinal microbiota of an infant, especially significantly enriching lactic acid bacteria in an intestinal tract, while reducing unclassified bacterial family and other miscellaneous bacteria.

An infant formula milk powder is rich in milk fat globule membrane protein, phospholipids, and oligosaccharides. A preparation method includes using raw cow milk as raw material, cleaning and pre-sterilizing raw cow milk, adding MFGM-rich whey protein powder, α-lactalbumin powder, galactooligosaccharides, polyfructoses and other ingredients into the pre-sterilized raw cow milk, and performing pre-sterilization, homogenization, sterilization, concentration, and spray drying. By means of formula adjustment, the contents of biologically active substances having special functional components such as MFGM-protein, lactoferrin, α-lactalbumin, total galactooligosaccharide, total polyfructose, sialic acid, total phospholipid, sphingomyelin, lecithin, phosphatidylserine, phosphatidylethanolamines, phosphatidylinositol, ganglioside, triglyceride and diglyceride in the infant formula milk powder are increased, thereby facilitating the colonization of probiotics in the intestinal microbiota of an infant, especially significantly enriching lactic acid bacteria in an intestinal tract, while reducing unclassified bacterial family and other miscellaneous bacteria.

In one aspect, the invention relates to a composition including a factor H binding protein (fHBP) and a Neisseria meningitidis non-serogroup B capsular polysaccharide. The invention further relates to uses of a composition that includes fHBP, such as, for example, uses to elicit an immune response against N. meningitidis serogroup B strains and non-serogroup B strains. The compositions and methods described herein are directed to administration in humans, including adults, adolescents, toddlers, and infants.

In one aspect, the invention relates to a composition including a factor H binding protein (fHBP) and a Neisseria meningitidis non-serogroup B capsular polysaccharide. The invention further relates to uses of a composition that includes fHBP, such as, for example, uses to elicit an immune response against N. meningitidis serogroup B strains and non-serogroup B strains. The compositions and methods described herein are directed to administration in humans, including adults, adolescents, toddlers, and infants.

A feed for enhancing immunity of tilapia and preparation method thereof, wherein the feed includes 20-30 parts of rice chaff, 15-25 parts of earthworm powder, 10-15 parts of shrimp shell powder, 10-15 parts of sodium alginate, 5-10 parts of oyster shell powder, 5-10 parts of cyclohexanone, 10-15 parts of honeysuckle extract, 3-5 parts of Commelina communis extract, 3-6 parts of β-1,3-glucan, 2-3 parts of flavomycin growth promoter, 1-3 parts of complex enzyme preparation, 5-8 parts of selenium methionine, 6-10 parts of distiller's grains, 1-3 parts of complex vitamins, 1-3 parts of complex trace elements and 2-3 parts of food attractant, in parts by weight.